Related references
Note: Only part of the references are listed.Employment and work-related issues in cancer survivors
Anja Mehnert
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Japan: Universal Health Care at 50 Years 2 Japanese universal health coverage: evolution, achievements, and challenges
Naoki Ikegami et al.
LANCET (2011)
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan
Takeru Shiroiwa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?
Anne Mason et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nonadherence to Imatinib during an Economic Downturn
Robin K. Kelley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Out-of-Pocket Expenses and Their Burden in Patients With Rheumatoid Arthritis
Frederick Wolfe et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Chronic myeloid leukemia in Asia
Wing Y. Au et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group
Mari Sakai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia
Tatsuya Kawaguchi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option
Linda Mileshkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cancer pain management at home (I): do older patients experience less effective management than younger patients?
Michael I. Bennett et al.
SUPPORTIVE CARE IN CANCER (2009)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study
EA Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)